5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Management Pearls on the Treatment of Actinic Keratoses and Field Cancerization

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Field cancerization (FC) is a chronic disease involving multiple clinical and subclinical actinic keratoses (AK) on large photo-exposed surfaces with multifocal areas of dysplasia and precancerous changes. Patients and treatment must be properly monitored and managed to avoid aggravation and progression of the disease. Management of actinic keratoses includes lesion-directed treatments, such as cryotherapy and field-directed therapies. Field-directed therapies may have the potential to address subclinical damage, reduce AK recurrence rates and potentially reduce the risk of squamous cell carcinoma development. Multiple studies have demonstrated the efficacy of field-directed treatments, including 5-fluorouracil, photodynamic therapy, imiquimod, chemical exfoliation with trichloroacetic acid and diclofenac gel, for multiple AK and FC. The choice of therapy should be based on multiple factors, such as efficacy, tolerability, patient risk profile, costs and cosmetic results. Management of AK includes not only treatment but also prevention. Medical devices, such as sunscreens containing liposome-encapsulated DNA repair enzymes, can repair DNA damage associated with chronic UV radiation and reduce the number of new AK lesions. Here we provide therapeutic pearls and expert opinions on the treatment of AK and FC (as monotherapy or in combination) with the overall aim to achieve better, faster, and well-tolerated clinical responses.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications - actinic keratoses, Bowen's disease, basal cell carcinoma.

          Topical photodynamic therapy (PDT) is a widely used non-invasive treatment for certain non-melanoma skin cancers, permitting treatment of large and multiple lesions with excellent cosmesis. High efficacy is demonstrated for PDT using standardized protocols in non-hyperkeratotic actinic keratoses, Bowen's disease, superficial basal cell carcinomas (BCC) and in certain thin nodular BCC, with superiority of cosmetic outcome over conventional therapies. Recurrence rates following PDT are typically equivalent to existing therapies, although higher than surgery for nodular BCC. PDT is not recommended for invasive squamous cell carcinoma. Treatment is generally well tolerated, but tingling discomfort or pain is common during PDT. New studies identify patients most likely to experience discomfort and permit earlier adoption of pain-minimization strategies. Reduced discomfort has been observed with novel protocols including shorter photosensitizer application times and in daylight PDT for actinic keratoses.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The optics of human skin.

            An integrated review of the transfer of optical radiation into human skin is presented, aimed at developing useful models for photomedicine. The component chromophores of epidermis and stratum corneum in general determine the attenuation of radiation in these layers, moreso than does optical scattering. Epidermal thickness and melanization are important factors for UV wavelengths less than 300 nm, whereas the attenuation of UVA (320-400 nm) and visible radiation is primarily via melanin. The selective penetration of all optical wavelengths into psoriatic skin can be maximized by application of clear lipophilic liquids, which decrease regular reflectance by a refractive-index matching mechanism. Sensitivity to wavelengths less than 320 nm can be enhanced by prolonged aqueous bathing, which extracts urocanic acid and other diffusible epidermal chromophores. Optical properties of the dermis are modelled using the Kubelka-Munk approach, and calculations of scattering and absorption coefficients are presented. This simple approach allows estimates of the penetration of radiation in vivo using noninvasive measurements of cutaneous spectral remittance (diffuse reflectance). Although the blood chromophores Hb, HbO2, and bilirubin determine dermal absorption of wavelengths longer than 320 nm, scattering by collagen fibers largely determines the depths to which these wavelengths penetrate the dermis, and profoundly modifies skin colors. An optical "window" exists between 600 and 1300 nm, which offers the possibility of treating large tissue volumes with certain long-wavelength photosensitizers. Moreover, whenever photosensitized action spectra extend across the near UV and/or visible spectrum, judicious choice of wavelengths allows some selection of the tissue layers directly affected.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017

                Bookmark

                Author and article information

                Contributors
                j.piquero@dermik.es
                Journal
                Dermatol Ther (Heidelb)
                Dermatol Ther (Heidelb)
                Dermatology and Therapy
                Springer Healthcare (Cheshire )
                2193-8210
                2190-9172
                17 July 2020
                17 July 2020
                October 2020
                : 10
                : 5
                : 903-915
                Affiliations
                [1 ]Dermik Clinica Dermatológica Multidisciplinar, Barcelona, Spain
                [2 ]GRID grid.5841.8, ISNI 0000 0004 1937 0247, Dermatology Department, Hospital Clínic de Barcelona, , Universitat de Barcelona, ; Barcelona, Spain
                [3 ]GRID grid.411106.3, ISNI 0000 0000 9854 2756, Dermatology Department, Instituto de Investigación Sanitaria (IIS) Aragón, , Miguel Servet University Hospital, ; Zaragoza, Spain
                [4 ]Dermatology Department, Hospital de L’Esperit Sant, Santa Coloma de Gramenet, Barcelona, Spain
                [5 ]GRID grid.411129.e, ISNI 0000 0000 8836 0780, Dermatology Department, , Hospital Universitari Bellvitge, ; Barcelona, Spain
                [6 ]GRID grid.487221.a, ISNI 0000 0004 1795 1224, Innovation and Development, , ISDIN, ; Barcelona, Spain
                [7 ]GRID grid.411316.0, ISNI 0000 0004 1767 1089, Dermatology Department, , Hospital Universitario Fundación Alcorcón, ; Madrid, Spain
                Author information
                http://orcid.org/0000-0002-4481-5602
                Article
                425
                10.1007/s13555-020-00425-4
                7477025
                32681454
                41dc3e63-09da-4725-8713-d9d562d10955
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 4 June 2020
                Funding
                Funded by: ISDIN Labs (ES)
                Award ID: Publication costs are supported by ISDIN
                Categories
                Practical Approach
                Custom metadata
                © The Author(s) 2020

                Dermatology
                actinic keratosis,chemical peels,cutaneous field cancerization,photoaging,photo-carcinogenesis,photodynamic therapy,photolyase,sunscreens,5-fu

                Comments

                Comment on this article